Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05773001 · ClinicalTrials.gov registry record · Phase 1

Macrophage Regulation of Ozone-Induced Lung Inflammation

A Phase 1 study of SARS-CoV-2 Pneumonia, sponsored by Robert Tighe, MD.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
1
Study location

NCT05773001: Recruiting Phase 1 study of SARS-CoV-2 Pneumonia, sponsored by Robert Tighe, MD.

NCT05773001 is a Phase 1 study of SARS-CoV-2 Pneumonia that is actively recruiting participants, run by Robert Tighe, MD. The registered enrollment target is 100 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05773001, a Phase 1 study of SARS-CoV-2 Pneumonia, is actively recruiting participants, sponsored by Robert Tighe, MD.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.

Primary Outcome

Change in the abundance of monocyte-derived alveolar macrophages and association to measures of O3-induced inflammation (BAL cell neutrophils, albumin and cytokine production)

Conditions Studied

Interventions

  • DRUG Ozone

Study Locations (1)

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-05-18
Est. Completion 2028-05
Phase Phase 1
Robert Tighe, MD

3 total trials

What NCT05773001 shows while recruiting

NCT05773001 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% higher).

The record links to 1 condition, with SARS-CoV-2 Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which Ozone is the first listed.

NCT05773001 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05773001 about?

NCT05773001 is a clinical study titled "Macrophage Regulation of Ozone-Induced Lung Inflammation". The purpose of this research study to understand how prior respiratory infections affect the susceptibility to lung inflammation following environmental exposures.

What is the current status of trial NCT05773001?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2023-05-18. Estimated completion is 2028-05.

What conditions does trial NCT05773001 study?

This clinical trial studies the following conditions: SARS-CoV-2 Pneumonia.

What interventions are being tested in trial NCT05773001?

The interventions under investigation include: Ozone (DRUG).

Who is sponsoring clinical trial NCT05773001?

This trial is sponsored by Robert Tighe, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05773001 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT05773001's enrollment target sits among peer trials

100 547th of 2000 higher than 1,411 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05773001, the US trial registry maintained by the National Library of Medicine. NCT05773001 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.